FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024 16:02 ET
|
FibroGen, Inc.
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination...
Non-metastatic Prostate Cancer (nmPC) Market, Epidemiology, and Forecast - Strategic Insight until 2032
January 24, 2024 10:39 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Non-metastatic Prostate Cancer (nmPC) - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's...
Prostate Cancer Drugs Global Market Report 2024: Emerging Combination Therapies and Geographic Expansion to Propel the Global Prostate Cancer Drugs Market Through 2028
January 22, 2024 16:58 ET
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Prostate Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This recent comprehensive study sheds...
Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032
January 04, 2024 18:33 ET
|
Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This...
Global Prostate Cancer Drugs Market Shows Robust Growth, Projected to Reach $23.50 Billion in 2027
July 24, 2023 05:08 ET
|
Research and Markets
Dublin, July 24, 2023 (GLOBE NEWSWIRE) -- The "Prostate Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global prostate cancer drugs market...
Global Prostate Cancer Clinical Landscape Market Report 2021: Treatments, Epidemiology, Marketed Drugs, Pipeline Drugs, Regulatory Events, Clinical Trials, Drug Assessment, Future Trends
July 14, 2021 05:03 ET
|
Research and Markets
Dublin, July 14, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Prostate Cancer" report has been added to ResearchAndMarkets.com's offering. The publisher estimates that in 2018, there were 1.3...
US Prostate Cancer Drug Market Outlook to 2026: Comprehensive Clinical Insight on 25 FDA Approved Prostate Cancer Drugs
February 10, 2021 03:38 ET
|
Research and Markets
Dublin, Feb. 10, 2021 (GLOBE NEWSWIRE) -- The "US Prostate Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. ...
Global Castrate Resistant Prostate Cancer Pipeline Insight Report 2020 Featuring Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma & ESSA Pharma
January 11, 2021 05:03 ET
|
Research and Markets
Dublin, Jan. 11, 2021 (GLOBE NEWSWIRE) -- The "Castrate Resistant Prostate Cancer - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This "Castrate...
Worldwide Prostate Cancer Industry to 2024 - Insights & Forecast with Potential Impact of COVID-19
December 23, 2020 07:18 ET
|
Research and Markets
Dublin, Dec. 23, 2020 (GLOBE NEWSWIRE) -- The "Global Prostate Cancer Market (by Cancer Type, Drug, Therapy & Region): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)"...
Telix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study
August 07, 2019 20:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and SYDNEY, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...